PsyTech is building a psychedelic health and wellness ecosystem, designed to elevate psychedelic medicine, foster normalization and accelerate innovation. PsyTech Summits bring together an engaged, passionate, and focused community of psychedelic industry players, researchers, and consumers.
Hayim is an adventurous business leader driven by the double bottom line of doing well financially and doing good in the world. He is experienced in international business development and financing and has spent his career building global healthcare companies for over 20 years. Recently, Hayim led iCAN’s Incubator, and took the helm at PsyTech in February 2020.
In his 15 years’ experience as a CPA, Mark has owned his own business, providing tax, consulting and CFO services to select clients. He served as a founding shareholder and CFO for two pharmaceutical cannabis companies, both of which resulted in exits as sales to public companies. Being a business leader in the cannabis space, Mark is well positioned to support PsyTech.
Carey is an experienced, creative and hard-working marketing executive with 15+ years of strategic, hands-on marketing experience. She knows that no job is too big or too small for a marketing exec and prides herself on building capable, inspired teams that deliver results aligned with business goals. She is a passionate about building solid businesses around great ideas.
Yaron is a product development specialist and has been involved in several "First-in-Human" clinical trials, taking multiple companies through FDA and European regulatory approval. Having served as the Director of Life Sciences at iCAN, Yaron has the experience and knowledge necessary to guide our clinical and regulatory efforts forward.
Visit MindMedAustralia
The two-day Summit on Psychedelic Therapies for Mental Illness will bring together clinicians, scientists, academics, mental and public health professionals, philanthropists, Government, law and policy makers, business, industry, consumers and other interested stakeholders. The event will be preceded by a two-day workshop program for therapists, health professionals and members of the public with leading international facilitators.
https://hakomiinstitute.com/
Keren Tzarfaty, Ph.D. is the co-founder of the Hakomi Institute of Israel a trainer for MAPS in Israel (Multidisciplinary Association for Psychedelic Studies). She is a clinical investigator in the MDMA PTSD FDA approved clinical trial, examining the impact of MDMA assisted psychotherapy on severe PTSD patients
Christian Angermayer is an entrepreneur and investor and the founder of Apeiron Investment Group, his family office and merchant banking business. Apeiron focuses on Financial Services (especially fintech and crypto assets), Technology, Life Sciences, Media & Entertainment and Real Estate & Prop-Tech. Apeiron completes deals across the entire lifecycle and balance sheet of a company, from non-listed Seed/Start Up investments to larger scale Restructuring and Special Situations deals (mostly listed), and additionally also invests in venture and private equity funds.
In 2000, Christian co-founded Ribopharma (original patents for RNAi technology) which merged with stock market listed US SPAC Alnylam in 2003 and has a USD 13bn market cap today. Since then, Christian has created, co-founded and invested in numerous successful companies, has raised over USD 2bn for his portfolio companies and has been involved in more than 50 successful IPO- and M&A-transactions either as an entrepreneur, investor or banker/advisor.
Today, Christian is one of the most active and significant investors in European fintech companies with a special focus on crypto-currencies and blockchain-related business models. Apeiron’s cryptocurrency investments are mainly done via its subsidiary CRYPTOLOGY Asset Group PLC. Among various other investments, Cryptology is the largest institutional shareholder of Block.One, the company behind EOS, one of the most successful protocol tokens.
With his biotech company ATAI Life Sciences, Christian has the ambitious goal to develop solutions for the more than 300 million people who suffer from depression, especially by bringing back formerly vilified drugs like psychedelics into the legal realm. With his biotech companies REJUVERON and CAMBRIAN, Christian is developing drugs and technologies which have the potential to significantly prolong human life span and ultimately defeat death.
In addition to his entrepreneurial activities, Christian places great value on social, political and societal commitments. He is a Young Global Leader of the World Economic Forum, a member of the Presidential Advisory Council of His Excellency President Paul Kagame of Rwanda and a member of the Milken Institute Young Leaders Circle. Christian is a board member of Vienna-based Hayek Institute, a Libertarian and free-markets-focused think-tank and a member of The Court of the London School of Hygiene and Tropical Medicine.
Christian’s “Angermayer Policy and Innovation Forum” convenes several times a year Head of States, leading politicians, investors and scientists to discuss crucial topics and issues.
Passionate about the arts and film, Christian has (executive) produced 21 feature films including critically acclaimed movies like FILTH, ASPERN PAPERS and HECTOR AND THE SEARCH FOR HAPPINESS. He is the largest shareholder of DEAG, the largest live entertainment company in Europe, producing over 4.500 shows per year from pop to classic and from exhibitions to family entertainment. Christian has a unique art collection centred around the theme „Psychedelics / Entheogens”.
Founder & Co-CEO @ Mindmed
JR is a former Silicon Valley tech executive who realized that transformational solutions to mental illness and addiction might lie in psychedelic medicines. He spent 2 years researching and began personally investing in psychedelic research through his investment company. JR partnered with drug development veteran Stephen Hurst to start Mindmed in 2019, assembling a leading clinical drug discovery and development team with vast experience conducting clinical trials and research on drug candidates derived from psychedelics. Before starting Mindmed, JR worked in market expansion and operations at Uber. After leaving Uber, he was backed by the Silicon Valley tech accelerator Y Combinator for his company Upgraded. Upgraded is partnered with Apple to provide device financing for Apple customers in Europe.
Executive Director @ Multidisciplinary Association for Psychedelic Studies (MAPS)
Rick Doblin, Ph.D., is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard’s Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master’s thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients.
His undergraduate thesis at New College of Florida was a 25-year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He also conducted a thirty-four year follow-up study to Timothy Leary’s Concord Prison Experiment. Rick studied with Dr. Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner. His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in 1986, and currently resides in Boston with his wife, dog, and empty rooms from three children, one of whom is in college and two have graduated.
Entheos Science is spearheading innovation in the field of technology and biotechnology to provide a paradigm-shifting platform for reducing mental health disorders. We are capitalizing on profound changes in mental health treatments, which collectively are driving a secular shift towards powerful and soon to be un-banned substances being used to treat various disorders.
Synthesis offers safe, legal, medically supervised psychedelic retreats in Amsterdam. We make the psychedelic experience accessible for curious individuals who want to utilize moderate-to-high doses of psilocybin truffles to catalyze creative breakthroughs, explore consciousness, find meaning, improve confidence, and search for a mystical experience.
iCAN is building the cannabis ecosystem; iCAN has identified and accelerated a portfolio of innovative companies, creating synergies and cooperation across the industry at large. iCAN uses its global network and reach to position Israel as the leading medical cannabis tech hub. iCAN is the power behind CannaTech, the premier international cannabis summit.
